Akbar Michael, Abel Rainer, Seyler Thorsten M, Bedke Jens, Haferkamp Axel, Gerner Hans J, Möhring Klaus
Department of Orthopaedic Surgery, University of Heidelberg, Heidelberg, Germany.
BJU Int. 2007 Sep;100(3):639-45. doi: 10.1111/j.1464-410X.2007.06977.x. Epub 2007 May 26.
To examine the effects of repeated detrusor injections of botulinum-A toxin (BTX) for possible changes in bladder function, muscular structure of the detrusor, increase in BTX tolerance (tachyphylaxis) and side-effects, as BTX is a new treatment alternative for patients with a neurogenic bladder condition that is difficult to treat and refractory to anticholinergic medication.
Between 2000 and 2005, 19 patients with myelodysplasia (MDP) and 25 spinal cord-injured (SCI) patients were treated with repeated suburothelial BTX injections (Dysport, Ipsen-Pharma, Ettlingen, Germany) or injections into the intramural detrusor. The follow-up was > or = 3 years (range 3-5, median 4.5).
Detrusor compliance, bladder capacity, and detrusor pressure at maximum filling improved significantly (P < 0.001) compared to baseline after each BTX injection. There was prolonged efficacy of each BTX administration and all repeated injections in the paediatric and adult patients with neurogenic bladder dysfunction over a median follow-up of 4.5 years. There was no evidence for drug tolerance or changes in the morphological appearance of the bladder. Safety was good: no complications were associated with the injection procedure itself. Early in the treatment programme, three patients who received a dose of 1000 units Dysport showed systemic side-effects and generalized muscle weakness. These resolved without intervention and did not recur after reducing the adult dose to 750 units (paediatric dose 20 units/kg, not >400 units), which seems to be the optimum for good efficacy with an adequate safety margin.
BTX injection is a safe and effective treatment for neurogenic detrusor hyperreflexia. Repeat treatments are as effective as the first: there was no indication of a lack of efficacy due to tachyphylaxis, antibody formation, or fibrosis of the detrusor muscle in this sample.
肉毒杆菌A毒素(BTX)是治疗难治性神经源性膀胱疾病患者的一种新的治疗选择,本研究旨在探讨反复向逼尿肌注射BTX对膀胱功能、逼尿肌肌肉结构、BTX耐受性增加(快速耐受)及副作用的影响。
2000年至2005年间,19例脊髓发育不良(MDP)患者和25例脊髓损伤(SCI)患者接受了反复的膀胱黏膜下BTX注射(Dysport,益普生制药公司,德国埃特林根)或壁内逼尿肌注射。随访时间≥3年(范围3 - 5年,中位数4.5年)。
与每次BTX注射前的基线相比,逼尿肌顺应性、膀胱容量和最大充盈时的逼尿肌压力均显著改善(P < 0.001)。在中位随访4.5年期间,对于患有神经源性膀胱功能障碍的儿童和成人患者,每次BTX给药及所有重复注射均有延长的疗效。没有证据表明存在药物耐受性或膀胱形态外观的改变。安全性良好:注射过程本身未出现并发症。在治疗方案早期,3例接受1000单位Dysport剂量的患者出现全身副作用和全身肌肉无力。这些症状未经干预自行缓解,在将成人剂量降至750单位(儿童剂量20单位/千克,不超过400单位)后未再次出现,这似乎是具有足够安全边际的良好疗效的最佳剂量。
BTX注射是治疗神经源性逼尿肌反射亢进的一种安全有效的方法。重复治疗与首次治疗效果相同:在本样本中,没有迹象表明由于快速耐受、抗体形成或逼尿肌纤维化导致疗效不佳。